目的：对TGF-β1的G-800A，C-509T，T869C和G915C多态性位点与IgA肾病及其临床表现之间的相关性进行了分析。方法：纳入119例经肾活检证实为IgA肾病的患者和116例健康正常成人作为对照组。采用多聚酶链式反应-限制片段长度多态性分析和多聚酶链式反应-扩增受阻突变体系方法测定TGF-β1的G-800A，C-509T，T869C和G915C多态性位点的基因型，分析其与IgA肾病发病以及临床表现的相关性。结果：研究对象中G-800A和G+915C这两个位点没有多态性。IgAN患者C-509T位点的等位基因型分布与正常对照具有显著性差异（Ｐ＜0.05），且IgAN患者TT纯合子的频率显著高于对照组（33% vs 20%,Ｐ=0.02）。C869T位点等位基因的分布无显著性差异。C-509T和C869T位点等位基因分布和患者临床表现无明显的相关性。结论：TGF-β1基因C-509T位点的T等位基因携带可能与IgA肾病的发病易感性具有相关性。
ObjectiveTo investigate the protective effect of Roux-en-Y gastric bypass surgery on early damage of renal tissue in type 2 diabetes mellitus rats, and explore the mechanism of the protective effects. MethodsDiabetes mellitus animal models were induced by intraperitoneal injection of streptozotocin (STZ, 35 mg /kg) and a high-fat diet.Diabetic rats were divided into three groups randomly (digital table method): diabetes control group (n=8), sham operation group (n=8), and Roux-en-Y gastric bypass group (n=14).Another 8 normal SD rats as the normal control group.The fasting blood glucose, serum total cholesterol (TC), triglyceride (TG), and free fatty acid (FFA) were measured before operation and in 8 weeks after operation; plasma BUN and Cr were measured respectively before operation and in 4 and 8 weeks after operation in each group rats, 24 h urine microalbumin and urine 8-hydroxydeoxyguanosine were measured respectively before operation and in 8 weeks after operation in each group rats.Renal pathological changes were observed and the indexes of kidney hypertrophy, the mean glomerular area (MGA), and the mean glomerular volume (MGV) were analyzed in 8 weeks after operation.The expressions of fibronectin, typeⅣcollagen (CoⅣ), transforming growth factor-β1 (TGF-β1), intercellular adhesion molecule-1(ICAM-1), nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4), and Bcl-2 protein in renal tissues were investigated by immunohistochemical staining. ResultsRoux-en-Y gastric bypass surgery could reduce the blood glucose, blood lipid, MGA, MGV, and the index of kidney hypertrophy of diabetic rats significantly (P < 0.05), improved renal pathological morphology and kidney function (P < 0.05), reduced the protein expressions of fibronectin and CoⅣ, decreased the protein expressions of TGF-β1, ICAM-1, and NOX4, and increased the protein expression of Bcl-2. ConclusionRoux-en-Y gastric bypass surgery can improve kidney function and the pathological damage of diabetes rats, its mechanism may be related to inhibition the protein expressions of TGF-β1, ICAM-1, and NOX4, and increase the protein expression of Bcl-2.
ObjectiveTo systematically review the independent physical risk factors associated with diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus. MethodsWe searched MEDLINE, EMbase, CBM, CNKI and VIP for all studies about the independent physical risk factors associated with diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus up to December 2012. Two reviewers independently screened studies according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of included studies. Then meta-analysis was conducted using RevMan 5.2 software. ResultsA total of 11 studies involving 12 957 patients with type 2 diabetes were included. Of these 11 studies, 9 were cross-sectional studies, two were cohort studies, and one was case-control study. The results showed that:the main physical factors associated with DKD were:duration of diabetes (OR=1.11, 95%CI 1.05 to 1.18), waist circumference (OR=1.02, 95%CI 1.00 to 1.04), fasting glucose (OR=1.11, 95%CI 1.07 to 1.16), glycosylated hemoglobin (OR=1.20, 95%CI 1.06 to 1.36), systolic blood pressure (OR=1.03, 95%CI 1.02 to 1.05), diastolic blood pressure (OR=2.41, 95%CI 1.15 to 4.64), triglycerides (OR=1.24, 95%CI 1.02 to 1.51), high-density lipoprotein (OR=0.558, 95%CI 0.369 to 0.844), blood uric acid (OR=1.005, 95%CI 1.002 to 1.009), blood urea nitrogen (OR=1.58, 95%CI 1.37 to 1.82), past history of kidney disease (OR=3.26, 95%CI 1.20 to 8.87) and family history of kidney disease (OR=1.83, 95%CI 1.29 to 2.60). ConclusionCurrent evidence shows that multiple physical factors were associated with the development of type 2 diabetic kidney disease. However, due to the limited quantity and quality of the included studies, more high quality studies are needed to verify the conclusion.
Objective To systematically evaluate the effectiveness and safety of mycophenolate mofetil (MMF) for IgA Nephropathy (IgAN). Methods Databases including CNKI, CBM, MEDLINE, PubMed, The Cochrane Library and SCI were searched from January 1997 to January 2012, and the domestic conference data and relevant published articles were also searched manually. All randomized controlled trials (RCTs) on MMF in treating IgAN were independently collected and screened according to the inclusion and exclusion criteria by two reviewers. The data were extracted, the quality of the included studies was assessed and cross-checked, and then meta-analysis was conducted using RevMan 5.0 software. Results A total of 8 RCTs involving 272 patients with IgAN were included. The results of meta-analyses showed that: a) There were no significant differences in the overall effective rate (RR=0.72, 95%CI 0.21 to 2.52, P=0.61) between the MMF group and the placebo group, but the overall effective rate was higher in the MMF+hormone group than the CTX+hormone group (RR=4.21, 95%CI 1.86 to 9.53, Plt;0.000 1) and other immunosuppressants +hormone groups (RR=3.03, 95%CI 1.47 to 6.25, P=0.003); and b) Adverse reaction: The overall incidence rate of adverse reaction in the MMF+hormone group was lower than the CTX+hormone group (RR=0.16, 95%CI 0.07 to 0.37, Plt;0.000 1). There were no significant differences in the elevated serum creatinine rate (RR=2.28, 95%CI 0.65 to 7.94, P=0.20) and the case number of developing end-stage renal disease (ESRD) (RR=2.37, 95%CI 0.44 to 12.83, P=0.32) between the MMF group and the control group. Conclusion MMF combined with hormone in treating IgAN can increase the overall effective rate and decrease the overall incidence rate of adverse reaction, but its effectiveness of improving long-term survival rate has to be further proved by conducting more high-quality, multi-center and large-scale clinical trials. MMF alone has the same effect as the placebo dose, and it shows no differences in elevated serum creatinine after the treatment compared with conventional therapies.
目的：研究吗替麦考酚酯（MMF）和环孢素A（CsA）对大鼠慢性移植肾病中细胞保护基因A20、HO-1、Bcl-2和Bcl-XL表达的影响。方法：分别采用雄性SD大鼠和Wistar大鼠作为供受体建立强化缺血/再灌注损伤慢性移植肾病模型。对受者依据所采用的免疫抑制剂方案分组：对照组、CsA组、MMF组。在移植术后的相同时间点处死大鼠，切取移植肾脏。采用荧光定量RTPCR和免疫组织化学方法检测A20、HO-1、Bcl2和BclXL的表达及其在移植肾中的定位情况。结果：在大鼠慢性移植肾病模型中，能够检测到所有上述四种细胞保护基因的表达。A20主要表达于血管内皮细胞和浸润之淋巴细胞。HO-1主要表达于浸润之淋巴细胞，但在肾小管上皮细胞也有表达。Bcl2和BclXL则主要表达于肾小管上皮细胞。MMF组A20的表达显著高于CsA组和对照组（Plt;0.01）。HO1，Bcl2和BclXL的表达在MMF组和CsA组间无显著性差异（Pgt;0.05）。结论：MMF对A20表达的增强可能与MMF减轻大鼠慢性移植肾病病变的机制有关。
目的:观察黄芪注射液治疗糖尿病肾病的临床疗效。 方法:将116例糖尿病肾病患者随机分为治疗组和对照组,治疗组在对照组的基础上同时使用黄芪注射液,观察治疗后4周24小时尿蛋白定量、血肌酐、尿素氮、血尿β2微球蛋白、甘油三酯、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、血尿酸等变化.结果:治疗组治疗后24小时尿蛋白定量、血尿酸均有不同程度的改善,与治疗前比较Plt;0.05,治疗组与对照组比较Plt;0.05。而血尿β2微球蛋白、血胆固醇无明显变化。结论:黄芪注射液对糖尿病肾病有较好的疗效。
目的 总结反复黏膜感染的IgA肾病的临床病理特点。 方法 采用单中心流行病学调查及回顾性研究，收集2006年1月－2009年12月253例经肾活检确诊为IgA肾病的住院患者的临床病理资料，对114例反复黏膜感染的IgA肾病患者（A组）及139例偶发或从未发生黏膜感染的IgA肾病患者（B组）的临床病理指标进行比较。 结果 A组患者年龄较B组小（t=2.913，P=0.004），临床表现无明显症状者比例较B组多，临床分型以反复发作肉眼血尿型为多，病理分级较B组轻（Z=?2.042，P=0.041），IgA+IgM+C3沉积率高（P＜0.001）；B组IgA+IgG+C3沉积率高（P＜0.001），纤维连接蛋白沉积率高（P＜0.001）。 结论 反复黏膜感染的IgA肾病组患者年龄小，反复发作肉眼血尿型多，临床表现及病理分级较轻；两组FN沉积及免疫球蛋白沉积的主要类型不同，提示两组发病机制可能有所不同。